首页> 外文期刊>Journal of vascular and interventional radiology: JVIR >Association of PI3K Pathway Mutations with Early Positron-Emission Tomography/CT Imaging Response after Radioembolization for Breast Cancer Liver Metastases: Results of a Single-Center Retrospective Pilot Study
【24h】

Association of PI3K Pathway Mutations with Early Positron-Emission Tomography/CT Imaging Response after Radioembolization for Breast Cancer Liver Metastases: Results of a Single-Center Retrospective Pilot Study

机译:与早期正电子发射断层扫描/ CT成像响应的PI3K途径突变与乳腺癌肝脏转移栓塞后的CT成像反应:单中心回顾试验研究的结果

获取原文
获取原文并翻译 | 示例
           

摘要

PurposeTo describe imaging response and survival after radioembolization for metastatic breast cancer and to delineate genetic predictors of imaging responses and outcomes. Materials and MethodsThis retrospective study included 31 women (average age, 52 y) with liver metastasis from invasive ductal carcinoma who underwent resin and glass radioembolization (average cumulative dose, 2.0 GBq ± 1.8) between January 2011 and September 2017 after receiving ≥ 3 lines of chemotherapy. Twenty-four underwent genetic profiling with MSK-IMPACT or Sequenom; 26 had positron-emission tomography (PET)/CT imaging before and after treatment. Survival after the first radioembolization and 2–4-month PET/CT imaging response were assessed. Laboratory and imaging features were assessed to determine variables predictive of outcomes. Unpaired Studentttests and Fisher exact tests were used to compare responders and nonresponders categorized by changes in fluorodeoxyglucose avidity. Kaplan–Meier survival analysis was used to determine the impact of predictors on survival after radioembolization. ResultsMedian survival after radioembolization was 11 months (range, 1–49 mo). Most patients (18 of 26; 69%) had complete or partial response based on changes in fluorodeoxyglucose avidity. Imaging response was associated with longer survival (P?= .005). Whereas 100% of patients with PI3K pathway mutations showed an imaging response, only 45% of wild-type patients showed a?response (P?= .01). Median survival did not differ between PI3K pathway wild-type (10.9 mo) and mutant (undefined) patients (P?=?.50). ConclusionsThese preliminary data suggest that genomic profiling may predict which patients with metastatic breast cancer benefit most from radioembolization. PI3K pathway mutations are associated with improved imaging response, which is associated with longer survival.
机译:purposeto描述了转移性乳腺癌放射性栓塞和描绘成像反应和结果的遗传预测因子后的成像反应和存活。材料和方法的回顾性研究包括31例女性(平均年龄,52 y),肝转移来自侵入性导管癌,在2011年1月和2017年1月之间接受树脂和玻璃放射性栓塞(平均累积剂量,2.0 GBQ±1.8),收到≥3行后化疗。二十四次接受遗传分析,具有MSK冲击或亮片; 26在治疗前后有正电子发射断层扫描(PET)/ CT成像。第一次放射性栓塞后生存和2-4个月的PET / CT成像响应进行了评估。评估实验室和成像特征,以确定预测结果的变量。 UNAPAIRED STUDESTESTS和FISHER精确测试用于比较氟脱氧葡萄糖耐酸性的变化对响应者和非反应者进行比较。 Kaplan-Meier生存率分析用于确定预测因子对放射性栓塞后存活的影响。 ReadicsMedian栓塞后的存活率为11个月(范围,1-49 mo)。大多数患者(18例,共26%)基于氟脱氧葡萄糖亲经的变化具有完全或部分响应。成像响应与较长的存活相关(P?= .005)。而100%的PI3K途径突变患者显示成像反应,只有45%的野生型患者显示出?响应(P?= .01)。 PI3K途径野生型(10.9MO)和突变体(未定义)患者(P?= 50)之间的中位生存率没有区别。结论初步数据表明,基因组分析可能预测哪种患有转移性乳腺癌的患者,从放射性栓塞中受益。 PI3K途径突变与改善的成像响应相关,其与更长的存活相关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号